County, Texas, 2007Texas, -2008. MTB isolates' susceptibility to moxifloxacin and ofloxacin 5 was determined with the agar proportion indirect susceptibility method. Spoligotype and 6 MIRU12-based genotyping of MTB isolates and sequencing of the gyrA, gyr B, Rv2686c, 7
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The anti-tuberculous drug pipeline is extremely slow: it has been more than 40 years 19 since rifampin was introduced for wide clinical use. While fluoroquinolones were 20 initially indicated and widely used for non-mycobacterial infections, their anti-21 tuberculous properties were recognized early and described in the literature (16) . Their 22 tolerability and relative low to moderate cost have made them an attractive target for 23 development as anti-tuberculous drugs. The newer generation of quinolones, such as 24 sparfloxacin, gatifloxacin and moxifloxacin have better in vitro activity against 25 Mycobacterium tuberculosis (MTB) clinical isolates than older generation quinolones, 26 such as ofloxacin, levofloxacin and ciprofloxacin, as suggested by lower minimum 27 inhibitory concentration (MIC), higher peak serum concentration to MIC ratio and [24] [25] [26] [27] [28] hour area under the curve to MIC ratio (11, 22, (27) (28) (29) 36) . In vivo studies in animal 29 models and humans have corroborated these findings (19, 34) . Due in part to the side 30 effects observed with sparfloxacin (phototoxicity) and gatifloxacin (dysglycemia), 31 moxifloxacin has been the quinolone to reach the furthest in clinical antimycobacterial 32 testing (4). Plans for further developing moxifloxacin as an anti-tuberculous agent to 33 shorten the course of TB chemotherapy are underway and clinicians are using the 34 medication when there is intolerance or resistance to first-line antituberculous agents. 35 However, there exists another dynamic that can potentially affect the use of moxifloxacin 36 in TB treatment: quinolones are one of the most widely prescribed antibiotics for 37 infections other than TB. In certain TB-endemic countries, quinolones can even be 38 purchased over the counter (20) . This raises the concern that MTB resistance to 39 moxifloxacin may develop due to reasons that are unrelated to its use as a TB treatment, 40 thus jeopardizing the usefulness of moxifloxacin as a first-line TB drug in the future. This 41 on December 23, 2017 by guest http://jcm.asm.org/ Downloaded from moxifloxacin using the agar proportion indirect susceptibility assay (3) . MTB strains that 66
showed ≥ 1% colony-growth at a moxifloxacin concentration of 0.5µg/ml or an ofloxacin 67 concentration of 2.0µg/ml were considered resistant to moxifloxacin or ofloxacin, 68 respectively. Of note, these breakpoints are used based on data in the literature that may 69 be inconclusive. We further determined the MIC of moxifloxacin in all moxifloxacin-70 resistant strains. The MIC was considered to be the lowest concentration that inhibited > 71 Houston. We performed quinolone susceptibility testing on 557 (87.8%) MTB isolates. 112
There were 77 MTB isolates that did not undergo testing due to non-viability (17 113 isolates), contamination (22 isolates) or lack of availability of isolates (38 isolates). 114
Resistance to moxifloxacin was found in 10 isolates (1.8%) during the study period. Five 115 isolates had a moxifloxacin MIC of 1µg/ml and 5 isolates had an MIC of 4µg/ml. We 116 found 100% concordance between resistance to moxifloxacin and ofloxacin. Although 117 information regarding prior quinolone treatments was not always complete, we found that 118 a quinolone was prescribed to 5 out of the 10 patients with moxifloxacin-resistant isolates 119 within two months prior to TB diagnosis (3 patients received moxifloxacin, 1 120 ciprofloxacin and 1 levofloxacin). There was one documented instance of transmission of 121 a moxifloxacin-resistant (and MDR) MTB isolate as confirmed by strain genotyping from 122 a mother to her 3-month old child. A comparison of the demographic, clinical and strain 123 characteristics of patients with moxifloxacin-sensitive TB and moxifloxacin-resistant TB 124 is shown in Table 1 that were not found in the moxifloxacin-susceptible isolates. The 2 isolates with the 140 A90V mutation had a moxifloxacin MIC of 1µg/ml. The isolates with the D94H, D94G 141 and D94A had moxifloxacin MIC of 4µg/ml, 4µg/ml and 1µg/ml, respectively. We did 142 not identify a resistance associated mutation in 5 of the moxifloxacin-resistant isolates 143 (50%). No other polymorphism in other regions of the GyrA, the GyrB or the Rv2686c-144 Rv2687c-Rv2688c genes existed at a higher frequency in the quinolone-resistant isolates 145 compared to the susceptible isolates (Table 2) . 146
147

Discussion 148
Using a population-based approach, we determined the moxifloxacin susceptibility in 149 87.8% of the MTB strains in Houston isolated over a 24-month period. We found that the 150 incidence of moxifloxacin resistance is low (1.8%) in an area of low TB incidence and 151 that there is a statistically significant association between moxifloxacin resistance and 152 MDR-TB. Despite incomplete data, we found that a quinolone antibiotic was prescribed 153 to at least half the patients with moxifloxacin-resistant TB in the period leading up to 154 their TB diagnosis. 
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We found no association between moxifloxacin resistance and the Beijing family 179 genotype, in contradistinction to data from Vietnam and Russia (9, 24) . The Beijing 180 genotype has been associated with drug resistance and MDR-TB in certain geographic 181 locations (especially Southeast Asia, Central Asia and Eastern Europe), but not in others 182 (7, 8, 13, 26) . In the case of quinolone drug resistance, this geographic disparity in 183 prevalence seems to apply as well. The reasons for the disparity are not clear, but 184 epidemiologic and host factors may play a role. 185
A mutation in the QRDR of GyrA was identified in only 50% of our 186 moxifloxacin-resistant isolates. No mutations were found in the QRDR of GyrB. In the 187 literature, 42-85% of quinolone-resistant MTB clinical isolates harbor a mutation in the 188 QRDR region of GyrA, and rarely in GyrB (12) . Consistent with findings from other 189 investigations, the isolates with the A90V mutation had a lower level of moxifloxacin 190 resistance (MIC=1µg/ml) than isolates with the D94G or D94H mutation which were 191 associated with higher level of resistance (MIC=4µg/ml) (1, 35) . An association between 192 MIC and a specific mutation could not be made, due to the small sample size. We did not 193 identify a quinolone-resistance-associated mutation in the Rv2686c-Rv2687c-Rv2688c 194 gene, which encodes a putative quinolone efflux pump. This could be due to the small 195 number of isolates, and sequencing of this gene in a larger sample size could yield a 196 different result. Alternatively, a different putative gene should be sequenced to account 197 for additional mutations that are associated with quinolone resistance. 
